| Viatris is a healthcare company. Co.'s portfolio comprises of approved molecules across a range of therapeutic areas, including brands, generic, complex generic and biosimilars. From cardiovascular health to oncology, Co. provides treatment options across therapeutic areas covering a variety of non-communicable and infectious diseases. Co. also provides support services such as diagnostic clinics, educational seminars and digital tools. Co. provides a range of treatment options across all its therapeutic areas, with several categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for optimal treatment. |
When researching a stock like Viatris, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from VTRS Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for VTRS stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of these ways is called the Relative Strength Index, or RSI. This popular indicator, originally developed in the 1970's by J. Welles Wilder, looks at a 14-day moving average of a stock's gains on its up days, versus its losses on its down days. The resulting VTRS RSI is a value that measures momentum, oscillating between "oversold" and "overbought" on a scale of zero to 100. A reading below 30 is viewed to be oversold, which a bullish investor could look to as a sign that the selling is in the process of exhausting itself, and look for entry point opportunities. A reading above 70 is viewed to be overbought, which could indicate that a rally in progress is starting to get crowded with buyers. If the rally has been a long one, that could be a sign that a pullback is overdue.